Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting
Portfolio Pulse from
Poseida Therapeutics presented positive interim Phase 1 results for its P-BCMA-ALLO1 therapy and preclinical data for P-CD19CD20-ALLO1 at the 66th ASH Annual Meeting. The data shows promising results in treating relapsed/refractory multiple myeloma and other cancers.
December 09, 2024 | 5:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Poseida Therapeutics reported positive interim results for its P-BCMA-ALLO1 therapy and preclinical data for P-CD19CD20-ALLO1, indicating strong potential in treating multiple myeloma and other cancers.
The positive interim results and preclinical data presented by Poseida Therapeutics at the ASH Annual Meeting suggest strong potential for their therapies in treating multiple myeloma and other cancers. This could lead to increased investor confidence and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100